Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
Identifieur interne : 000274 ( Main/Exploration ); précédent : 000273; suivant : 000275Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
Auteurs : Gökçe Eker Karatoprak [Turquie] ; Esra Küpeli Akkol [Turquie] ; Yasin Genç [Turquie] ; Hilal Bardakci [Turquie] ; Çi Dem Yücel [Turquie] ; Eduardo Sobarzo-Sánchez [Chili, Espagne]Source :
- Molecules (Basel, Switzerland) [ 1420-3049 ] ; 2020.
Abstract
Combretastatins are a class of closely related stilbenes (combretastatins A), dihydrostilbenes (combretastatins B), phenanthrenes (combretastatins C) and macrocyclic lactones (combretastatins D) found in the bark of Combretum caffrum (Eckl. & Zeyh.) Kuntze, commonly known as the South African bush willow. Some of the compounds in this series have been shown to be among the most potent antitubulin agents known. Due to their structural simplicity many analogs have also been synthesized. Combretastatin A4 phosphate is the most frequently tested compounds in preclinical and clinical trials. It is a water-soluble prodrug that the body can rapidly metabolize to combretastatin A4, which exhibits anti-tumor properties. In addition, in vitro and in vivo studies on combretastatins have determined that these compounds also have antioxidant, anti-inflammatory and antimicrobial effects. Nano-based formulations of natural or synthetic active agents such as combretastatin A4 phosphate exhibit several clear advantages, including improved low water solubility, prolonged circulation, drug targeting properties, enhanced efficiency, as well as fewer side effects. In this review, a synopsis of the recent literature exploring the combretastatins, their potential effects and nanoformulations as lead compounds in clinical applications is provided.
DOI: 10.3390/molecules25112560
PubMed: 32486408
PubMed Central: PMC7321081
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.</title>
<author><name sortKey="Karatoprak, Gokce Eker" sort="Karatoprak, Gokce Eker" uniqKey="Karatoprak G" first="Gökçe Eker" last="Karatoprak">Gökçe Eker Karatoprak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri</wicri:regionArea>
<wicri:noRegion>38039 Kayseri</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kupeli Akkol, Esra" sort="Kupeli Akkol, Esra" uniqKey="Kupeli Akkol E" first="Esra" last="Küpeli Akkol">Esra Küpeli Akkol</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara</wicri:regionArea>
<wicri:noRegion>06330 Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Genc, Yasin" sort="Genc, Yasin" uniqKey="Genc Y" first="Yasin" last="Genç">Yasin Genç</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bardakci, Hilal" sort="Bardakci, Hilal" uniqKey="Bardakci H" first="Hilal" last="Bardakci">Hilal Bardakci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul</wicri:regionArea>
<wicri:noRegion>34752 Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yucel, Ci Dem" sort="Yucel, Ci Dem" uniqKey="Yucel C" first="Çi Dem" last="Yücel">Çi Dem Yücel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri</wicri:regionArea>
<wicri:noRegion>38039 Kayseri</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sobarzo Sanchez, Eduardo" sort="Sobarzo Sanchez, Eduardo" uniqKey="Sobarzo Sanchez E" first="Eduardo" last="Sobarzo-Sánchez">Eduardo Sobarzo-Sánchez</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago, Chile.</nlm:affiliation>
<country xml:lang="fr">Chili</country>
<wicri:regionArea>Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago</wicri:regionArea>
<wicri:noRegion>8330507 Santiago</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela</wicri:regionArea>
<placeName><region nuts="2" type="communauté">Galice</region>
<settlement type="city">Santiago de Compostela</settlement>
</placeName>
<orgName type="university">Université de Saint-Jacques-de-Compostelle</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32486408</idno>
<idno type="pmid">32486408</idno>
<idno type="doi">10.3390/molecules25112560</idno>
<idno type="pmc">PMC7321081</idno>
<idno type="wicri:Area/Main/Corpus">000159</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000159</idno>
<idno type="wicri:Area/Main/Curation">000159</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000159</idno>
<idno type="wicri:Area/Main/Exploration">000159</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.</title>
<author><name sortKey="Karatoprak, Gokce Eker" sort="Karatoprak, Gokce Eker" uniqKey="Karatoprak G" first="Gökçe Eker" last="Karatoprak">Gökçe Eker Karatoprak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri</wicri:regionArea>
<wicri:noRegion>38039 Kayseri</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kupeli Akkol, Esra" sort="Kupeli Akkol, Esra" uniqKey="Kupeli Akkol E" first="Esra" last="Küpeli Akkol">Esra Küpeli Akkol</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara</wicri:regionArea>
<wicri:noRegion>06330 Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Genc, Yasin" sort="Genc, Yasin" uniqKey="Genc Y" first="Yasin" last="Genç">Yasin Genç</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bardakci, Hilal" sort="Bardakci, Hilal" uniqKey="Bardakci H" first="Hilal" last="Bardakci">Hilal Bardakci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul</wicri:regionArea>
<wicri:noRegion>34752 Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yucel, Ci Dem" sort="Yucel, Ci Dem" uniqKey="Yucel C" first="Çi Dem" last="Yücel">Çi Dem Yücel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri</wicri:regionArea>
<wicri:noRegion>38039 Kayseri</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sobarzo Sanchez, Eduardo" sort="Sobarzo Sanchez, Eduardo" uniqKey="Sobarzo Sanchez E" first="Eduardo" last="Sobarzo-Sánchez">Eduardo Sobarzo-Sánchez</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago, Chile.</nlm:affiliation>
<country xml:lang="fr">Chili</country>
<wicri:regionArea>Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago</wicri:regionArea>
<wicri:noRegion>8330507 Santiago</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela</wicri:regionArea>
<placeName><region nuts="2" type="communauté">Galice</region>
<settlement type="city">Santiago de Compostela</settlement>
</placeName>
<orgName type="university">Université de Saint-Jacques-de-Compostelle</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecules (Basel, Switzerland)</title>
<idno type="eISSN">1420-3049</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Combretastatins are a class of closely related stilbenes (combretastatins A), dihydrostilbenes (combretastatins B), phenanthrenes (combretastatins C) and macrocyclic lactones (combretastatins D) found in the bark of <i>Combretum caffrum</i>
(Eckl. & Zeyh.) Kuntze, commonly known as the South African bush willow. Some of the compounds in this series have been shown to be among the most potent antitubulin agents known. Due to their structural simplicity many analogs have also been synthesized. Combretastatin A4 phosphate is the most frequently tested compounds in preclinical and clinical trials. It is a water-soluble prodrug that the body can rapidly metabolize to combretastatin A4, which exhibits anti-tumor properties. In addition<i>,</i>
in vitro and in vivo studies on combretastatins have determined that these compounds also have antioxidant, anti-inflammatory and antimicrobial effects. Nano-based formulations of natural or synthetic active agents such as combretastatin A4 phosphate exhibit several clear advantages, including improved low water solubility, prolonged circulation, drug targeting properties, enhanced efficiency, as well as fewer side effects. In this review, a synopsis of the recent literature exploring the combretastatins, their potential effects and nanoformulations as lead compounds in clinical applications is provided.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32486408</PMID>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>11</Issue>
<PubDate><Year>2020</Year>
<Month>May</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Molecules (Basel, Switzerland)</Title>
<ISOAbbreviation>Molecules</ISOAbbreviation>
</Journal>
<ArticleTitle>Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E2560</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules25112560</ELocationID>
<Abstract><AbstractText>Combretastatins are a class of closely related stilbenes (combretastatins A), dihydrostilbenes (combretastatins B), phenanthrenes (combretastatins C) and macrocyclic lactones (combretastatins D) found in the bark of <i>Combretum caffrum</i>
(Eckl. & Zeyh.) Kuntze, commonly known as the South African bush willow. Some of the compounds in this series have been shown to be among the most potent antitubulin agents known. Due to their structural simplicity many analogs have also been synthesized. Combretastatin A4 phosphate is the most frequently tested compounds in preclinical and clinical trials. It is a water-soluble prodrug that the body can rapidly metabolize to combretastatin A4, which exhibits anti-tumor properties. In addition<i>,</i>
in vitro and in vivo studies on combretastatins have determined that these compounds also have antioxidant, anti-inflammatory and antimicrobial effects. Nano-based formulations of natural or synthetic active agents such as combretastatin A4 phosphate exhibit several clear advantages, including improved low water solubility, prolonged circulation, drug targeting properties, enhanced efficiency, as well as fewer side effects. In this review, a synopsis of the recent literature exploring the combretastatins, their potential effects and nanoformulations as lead compounds in clinical applications is provided.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karatoprak</LastName>
<ForeName>Gökçe Şeker</ForeName>
<Initials>GŞ</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Küpeli Akkol</LastName>
<ForeName>Esra</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Genç</LastName>
<ForeName>Yasin</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bardakci</LastName>
<ForeName>Hilal</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yücel</LastName>
<ForeName>Çiğdem</ForeName>
<Initials>Ç</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sobarzo-Sánchez</LastName>
<ForeName>Eduardo</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago, Chile.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Molecules</MedlineTA>
<NlmUniqueID>100964009</NlmUniqueID>
<ISSNLinking>1420-3049</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">combretaceae</Keyword>
<Keyword MajorTopicYN="N">combretastatins</Keyword>
<Keyword MajorTopicYN="N">drug discovery</Keyword>
<Keyword MajorTopicYN="N">nanoformulation</Keyword>
<Keyword MajorTopicYN="N">natural compound</Keyword>
<Keyword MajorTopicYN="N">structure-activity relationships</Keyword>
<Keyword MajorTopicYN="N">tubulin inhibitors.</Keyword>
</KeywordList>
<CoiStatement>The authors declare no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32486408</ArticleId>
<ArticleId IdType="pii">molecules25112560</ArticleId>
<ArticleId IdType="doi">10.3390/molecules25112560</ArticleId>
<ArticleId IdType="pmc">PMC7321081</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biomater Sci. 2019 Jun 25;7(7):2803-2811</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31062006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gynecol Oncol Res Pract. 2018 Jan 5;5:1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29318022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Chem. 2018 Aug;78:130-140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29554587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 May 03;6:25387</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27138035</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Lett. 2016 Sep 28;380(1):134-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27349166</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2004 Sep 10;111(4):604-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15239140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Oct 19;49(21):6412-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17034147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Planta Med. 2005 Feb;71(2):191-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15729632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Cent J. 2013 Dec 05;7(1):179</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24304592</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1997 May 15;57(10):1829-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9157969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2017 Dec 1;141:293-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29031074</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Pharmacol. 2016 Dec 23;7:506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28066252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Pharmacol. 2009;1(1):29-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20333321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncol Rep. 2013 Jun;29(6):2451-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23564200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3650-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12882819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Cancer. 2001 Mar 23;84(6):832-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11259100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 2005 Nov-Dec;25(6B):3865-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16309172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2001 Apr;7(4):1052-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11309357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2010 Nov;335(2):302-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20699436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Omega. 2018 Aug 22;3(8):9754-9769</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31459105</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Org Biomol Chem. 2019 Jun 26;17(25):6184-6200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31173031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 10;9(3):e85380</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24614859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Enzyme Inhib Med Chem. 2004 Dec;19(6):521-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15662956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fertil Steril. 2013 Nov;100(5):1459-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23993929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 1999 Sep 20;9(18):2711-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10509921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2005 Nov;115(11):2992-3006</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16224539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Oncol (Dordr). 2015 Dec;38(6):463-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26358135</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomaterials. 2010 Sep;31(27):7115-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20576288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Prod Rep. 2000 Jun;17(3):215-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10888010</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Prod Rep. 2003 Dec;20(6):558-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14700199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Lett. 2017 Nov 1;408:164-173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28888997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jul 28;436(7050):568-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16049491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Prod Commun. 2012 Aug;7(8):1051-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22978227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Mar 06;21(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32155790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine. 2012 Jan;8(1):81-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21664295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nat Prod. 1987 Jan-Feb;50(1):119-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3598594</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 1999 Jan-Feb;19(1A):189-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10226542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Khim. 2015 Jan-Feb;41(1):82-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26050475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Cancer. 1995 Apr;71(4):705-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7710932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2013 Dec 1;21(23):7381-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24139940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Thorac Surg. 2001 May;71(5):1657-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11383817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Agents Med Chem. 2013 Sep;13(7):1133-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23574386</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2009 May;26(5):1093-100</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19172383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Drug Des. 2000 Jun;15(3):203-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11049088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomed Nanotechnol. 2015 Jun;11(6):997-1006</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26353589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2012 Aug;54:22-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22647220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1999 Apr 1;59(7):1626-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10197639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 2002 Nov-Dec;22(6C):3933-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12553015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biophys J. 2012 May 2;102(9):2086-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22824272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2002 Mar;160(3):1097-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11891206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Molecules. 2019 Nov 26;24(23):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31779228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2000;476:311-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10949676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2012 Jan;29(1):178-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21789726</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2011 Apr 1;19(7):2306-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21397510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AAPS PharmSciTech. 2006 Apr 07;7(2):E32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16796350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Experientia. 1989 Feb 15;45(2):209-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2920809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vascul Pharmacol. 2016 Aug;83:78-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27235861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pharm. 2017 Jun 30;526(1-2):547-555</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28495582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medchemcomm. 2017 Jul 4;8(8):1592-1603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30108870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2018 Jun 6;10(22):18560-18573</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29767951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2015 Dec 29;11:93-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26766908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharmacol. 1988 Aug;34(2):200-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3412321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Pharmacol. 2020 Mar 24;11:339</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32265711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Ocul Pharmacol Ther. 2009 Jun;25(3):195-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19456253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2009 Feb;18(2):189-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19236265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncol Rep. 2013 Feb;29(2):585-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23232969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 1998 Nov 17;8(22):3153-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9873694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2008 Jun 1;18(11):3266-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18477509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2010 Dec;45(12):5752-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20933304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2003 May 5;13(9):1505-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12699742</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Jun 1;49(11):3033-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16722619</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2011;6:2337-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22072871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomater Sci. 2019 Dec 1;7(12):5283-5291</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31603448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2019 Mar 08;14:1789-1804</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30880980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Drugs. 2014 Apr;25(4):462-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24500030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Chem. 2017 Jun;72:130-147</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28460355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2010 Sep;27(9):1861-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20559700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2001 Sep 1;61(17):6413-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11522635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nat Prod. 2003 Jul;66(7):1022-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12880330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2011;18(20):3035-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21651481</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2019 Sep;37(15):4080-4091</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30451089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2017 Oct;106(10):3076-3083</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28619603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ChemMedChem. 2019 Dec 17;14(24):2052-2060</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31674147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1995 May 12;38(10):1666-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7752190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Biol Lett. 2013 Sep;18(3):368-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23818224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2019 Dec 1;183:111697</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31536891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest New Drugs. 2018 Aug;36(4):523-535</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29460212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1991 Aug;34(8):2579-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1875350</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Chili</li>
<li>Espagne</li>
<li>Turquie</li>
</country>
<region><li>Galice</li>
</region>
<settlement><li>Santiago de Compostela</li>
</settlement>
<orgName><li>Université de Saint-Jacques-de-Compostelle</li>
</orgName>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Karatoprak, Gokce Eker" sort="Karatoprak, Gokce Eker" uniqKey="Karatoprak G" first="Gökçe Eker" last="Karatoprak">Gökçe Eker Karatoprak</name>
</noRegion>
<name sortKey="Bardakci, Hilal" sort="Bardakci, Hilal" uniqKey="Bardakci H" first="Hilal" last="Bardakci">Hilal Bardakci</name>
<name sortKey="Genc, Yasin" sort="Genc, Yasin" uniqKey="Genc Y" first="Yasin" last="Genç">Yasin Genç</name>
<name sortKey="Kupeli Akkol, Esra" sort="Kupeli Akkol, Esra" uniqKey="Kupeli Akkol E" first="Esra" last="Küpeli Akkol">Esra Küpeli Akkol</name>
<name sortKey="Yucel, Ci Dem" sort="Yucel, Ci Dem" uniqKey="Yucel C" first="Çi Dem" last="Yücel">Çi Dem Yücel</name>
</country>
<country name="Chili"><noRegion><name sortKey="Sobarzo Sanchez, Eduardo" sort="Sobarzo Sanchez, Eduardo" uniqKey="Sobarzo Sanchez E" first="Eduardo" last="Sobarzo-Sánchez">Eduardo Sobarzo-Sánchez</name>
</noRegion>
</country>
<country name="Espagne"><region name="Galice"><name sortKey="Sobarzo Sanchez, Eduardo" sort="Sobarzo Sanchez, Eduardo" uniqKey="Sobarzo Sanchez E" first="Eduardo" last="Sobarzo-Sánchez">Eduardo Sobarzo-Sánchez</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000274 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000274 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= WillowV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32486408 |texte= Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32486408" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a WillowV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |